Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 2/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | GALR3 | O60755 | 1/20 | 0.39 |
| ▸ | FPR1 | P21462 | 1/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | LIPE | Q05469 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5158577 | 1.00 | FPR2 (0.46) | FPR2ROCK2SLC6A2NCF1SLC6A4 | |
| SCHEMBL5158579 | 1.00 | FPR2 (0.46) | FPR2ROCK2SLC6A2NCF1SLC6A4 | |
| Hydrochloric Acid SCHEMBL27460761 | 0.99 | FPR2 (0.45) | FPR2ROCK2SLC6A2NCF1SLC6A4 | |
| Hydrochloric Acid SCHEMBL6431288 | 0.98 | FPR2 (0.44) | FPR2ROCK2SLC6A2NCF1SLC6A4 | |
| Hydrochloric Acid SCHEMBL6431284 | 0.98 | FPR2 (0.44) | FPR2ROCK2SLC6A2NCF1SLC6A4 | |
| SCHEMBL1737760 | 0.90 | ROCK2 (0.41) | FPR2ROCK2SLC6A2NCF1SLC6A4 | |
| SCHEMBL1737717 | 0.90 | ROCK2 (0.41) | FPR2ROCK2SLC6A2NCF1SLC6A4 | |
| SCHEMBL1737713 | 0.90 | ROCK2 (0.41) | FPR2ROCK2SLC6A2NCF1SLC6A4 | |
| SCHEMBL6434969 | 0.89 | ROCK2 (0.44) | ROCK2SLC6A2NCF1HTR1AHTR2A | |
| SCHEMBL5606643 | 0.88 | ROCK2 (0.42) | FPR2ROCK2NCF1HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1113015-B1 | Optically active 3-((2-piperazinyl-phenyl)methyl)-1-(4-(trifluoromethyl)-phenyl)-2-pyrrolidinone compounds as 5-HT1D receptor selective antagonists | PFIZER PROD INC (US) | 2004-09-15 | — | — | EP | claimed |
| US-20030083337-A1 | Optically active 3-[(2-piperazinylphenyl)methyl]-1-[4-(trifluoromethyl)phenyl]-2-pyrrolidinone compounds as 5-HT1D receptor selective antagonists | PFIZER PRODUCTS, INC. | 2003-05-01 | — | — | US | claimed |
| US-20010039280-A1 | Optically active 3-[(2-Piperazinylphenyl)methyl]-1-[4-(trifluoromethyl)phenyl]-2-pyrrolidinone compounds as 5-HT 1D receptor selective antagonists | PFIZER PRODUCTS INC. | 2001-11-08 | — | — | US | claimed |
| EP-1113015-A1 | Optically active 3-((2-piperazinyl-phenyl)methyl)-1-(4-(trifluoromethyl)-phenyl)-2-pyrrolidinone compounds as 5-HT1D receptor selective antagonists | Pfizer Products Inc. (US) | 2001-07-04 | — | — | EP | claimed |
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| EP-1753460-A2 | COMBINATION OF ATYPICAL ANTIPSYCHOTICS AND 5-HT1B RECEPTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1737466-A1 | COMBINATION OF y-AMINOBUTYRIC ACID MODULATORS AND 5-HT-1b RECEPTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1703918-A2 | COMBINATION OF CRF ANTAGONISTS AND 5-HT 1B RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2006-09-27 | — | — | EP | disclosed |
| US-20050256112-A1 | Combination of atypical antipsychotics and 5HT-1B receptor antagonists | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
| WO-2005107808-A2 | COMBINATION OF ATYPICAL ANTIPSYCHOTICS AND 5-HT1B RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005082372-A1 | COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050182049-A1 | Combination of gamma-aminobutyric acid modulators and 5-HT1B receptor antagonists | PFIZER INC | 2005-08-18 | — | — | US | disclosed |
| US-20050171095-A1 | Combination of CRF antagonists and 5-HT1B receptor antagonists | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
| WO-2005067973-A2 | COMBINATION OF CRF ANTAGONISTS AND 5-HT 1B RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-07-28 | — | — | WO | disclosed |
| WO-2004091488-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| EP-1113015-B1 | Optically active 3-((2-piperazinyl-phenyl)methyl)-1-(4-(trifluoromethyl)-phenyl)-2-pyrrolidinone compounds as 5-HT1D receptor selective antagonists | PFIZER PROD INC (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20030083337-A1 | Optically active 3-[(2-piperazinylphenyl)methyl]-1-[4-(trifluoromethyl)phenyl]-2-pyrrolidinone compounds as 5-HT1D receptor selective antagonists | PFIZER PRODUCTS, INC. | 2003-05-01 | — | — | US | disclosed |
| US-20010039280-A1 | Optically active 3-[(2-Piperazinylphenyl)methyl]-1-[4-(trifluoromethyl)phenyl]-2-pyrrolidinone compounds as 5-HT 1D receptor selective antagonists | PFIZER PRODUCTS INC. | 2001-11-08 | — | — | US | disclosed |
| EP-1113015-A1 | Optically active 3-((2-piperazinyl-phenyl)methyl)-1-(4-(trifluoromethyl)-phenyl)-2-pyrrolidinone compounds as 5-HT1D receptor selective antagonists | Pfizer Products Inc. (US) | 2001-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039280-A1 | Optically active 3-[(2-Piperazinylphenyl)methyl]-1-[4-(trifluoromethyl)phenyl]-2-pyrrolidinone compounds as 5-HT 1D receptor selective antagonists | HTR1D, HTR1A, HTR5A | FPR2 539/4885ROCK2 1923/4885SLC6A2 462/4885 |
| US-20030083337-A1 | Optically active 3-[(2-piperazinylphenyl)methyl]-1-[4-(trifluoromethyl)phenyl]-2-pyrrolidinone compounds as 5-HT1D receptor selective antagonists | HTR1D, HTR1A, HTR3D | FPR2 568/4885ROCK2 1403/4885SLC6A2 544/4885 |
| US-20050256112-A1 | Combination of atypical antipsychotics and 5HT-1B receptor antagonists | HTR1B, HTR2B, HTR3B | FPR2 1345/4885ROCK2 3324/4885SLC6A2 59/4885 |
| US-20050182049-A1 | Combination of gamma-aminobutyric acid modulators and 5-HT1B receptor antagonists | HTR1B, HTR2B, HTR2A | FPR2 1747/4885ROCK2 4143/4885SLC6A2 92/4885 |
| US-20050171095-A1 | Combination of CRF antagonists and 5-HT1B receptor antagonists | HTR2B, HTR1B, HTR3B | FPR2 366/4885ROCK2 3417/4885SLC6A2 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.